Ritter Sivan, Zadik-Weiss Lilach, Almogi-Hazan Osnat, Or Reuven
Independent Consultant, Tel Aviv, Israel.
Independent Consultant, Amsterdam, The Netherlands.
Rambam Maimonides Med J. 2020 Jan 30;11(1):e0006. doi: 10.5041/RMMJ.10388.
Public health is connected to cannabis with regard to food, animal feed (feed), and pharmaceuticals. Therefore, the use of phytocannabinoids should be examined from a One Health perspective. Current knowledge on medical cannabis treatment (MCT) does not address sufficiently diseases which are of epidemiological and of zoonotic concern. The use of cannabinoids in veterinary medicine is illegal in most countries, mostly due to lack of evidence-based medicine. To answer the growing need of scientific evidence-based applicable medicine in both human and veterinary medicine, a new approach for the investigation of the therapeutic potential of cannabinoids must be adopted. A model that offers direct study of a specific disease in human and veterinary patients may facilitate development of novel therapies. Therefore, we urge the regulatory authorities-the ministries of health and agriculture (in Israel and worldwide)-to publish guidelines for veterinary use due to its importance to public health, as well as to promote One Health-related preclinical translational medicine studies for the general public health.
在食品、动物饲料和药品方面,公共卫生与大麻相关。因此,应从“同一健康”的角度审视植物大麻素的使用。目前关于医用大麻治疗(MCT)的知识并未充分涉及具有流行病学和人畜共患病学意义的疾病。在大多数国家,大麻素在兽医学中的使用是非法的,主要原因是缺乏循证医学依据。为满足人类和兽医学中对基于科学证据的适用药物日益增长的需求,必须采用一种新方法来研究大麻素的治疗潜力。一个能够直接对人类和兽医患者的特定疾病进行研究的模型可能会促进新疗法的开发。因此,我们敦促监管当局——(以色列及全球的)卫生部和农业部——鉴于其对公共卫生的重要性,发布兽用指南,并推动与“同一健康”相关的临床前转化医学研究,以促进公众健康。